Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated efficacy and safety data as well as new survival data on the clinical activity of KRX-0401 (perifosine) in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. Data from the study entitled "A Multicenter Phase 1/2 Study Evaluating the Safety and Efficacy of Perifosine (KRX-0401) + Bortezomib (Velcade(R)) in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma Who Were Previously Treated with Bortezomib," was presented on Saturday, December 5th at the 51st annual meeting of the American Society of Hematology, in a poster presentation by Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute.

Dr. Richardson presented updated results from the study as follows:

Trial Results:

Eighty-four patients with relapsed/refractory multiple myeloma were enrolled in a combined Phase 1/2 study (18 patients in the Phase 1 component and 66 patients in the Phase 2 component). The patients enrolled were heavily pre-treated with a median of 5 prior lines of therapy (range 1 - 13), including;

  • 100% of patients had been treated with bortezomib (55% of the patients were previously treated with at least two bortezomib-based therapies (range 1 - 4) and 81% were previously treated with bortezomib plus dexamethasone);
  • 98% of patients were previously treated with dexamethasone;
  • 94% of patients were previously treated with lenalidomide (Revlimid(R)) and/or thalidomide (Thalomid(R)); and
  • 58% of patients had prior stem cell transplant.

Overall Response Rate (ORR), defined as the percentage of patients achieving a complete, partial or mino
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has ... solution for use in portable vaporizers, which contains ... ingredients in cannabis, cannabidiol offers consumers a THC-free ... and other vaporizer technology. Photo - ... contains 483 different compounds which are currently known, ...
(Date:7/11/2014)... 2014 Research and Markets has ... Medical X-ray Film Industry Report 2014" report to ... Global And Chinese Medical X-Ray Film Industry ... the current state of the Global medical X-ray film ... The report provides a basic overview of the industry ...
(Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3
... Sept. 28 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... on the topic "Eye Diseases: Novel Therapies for Wet ... Citi,s 5th Annual Biotech Day on Tuesday, October 5, ... 8:00 a.m. Eastern Time and may be accessed through ...
... Inc. today announced that the U.S. Patent and ... another key patent application, "Mechanical Method and Apparatus ... matter covering the method of the INSORB Skin ... has now sold over 500,000 INSORB® Absorbable Skin ...
Cached Medicine Technology:Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent 2Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent 3
(Date:7/14/2014)... Carepoint has been designed specifically to facilitate ... intuitive interface for recording, sending, displaying and receiving ... reporting features. , Hall mc - an Ontario-based ... Rebecca de Witte to create this exciting new ... Carepoint provides seamless, real-time communication between the ...
(Date:7/14/2014)... COPENHAGEN Participation in activities that promote mental ... may help protect against the development of Alzheimer,s ... new research reported today at the Alzheimer,s Association ... , Research reported at AAIC 2014 also showed ... post-traumatic stress disorder (PTSD) may increase dementia ...
(Date:7/14/2014)... 2014 Spine Team Texas ... care—from diagnosis to treatment and recovery. Currently all physical ... in or training for certification in The McKenzie Method. ... completed the extensive program. , “We require certification of ... results in better outcomes for spine pain patients,” said ...
(Date:7/14/2014)... July 14, 2014 Cadeon Associates ... Turning Information into Money,” today announced that it ... global program that helps partners resell, deploy, and ... Spotfire® analytics platform. TIBCO Software Inc. is a ... including TIBCO Spotfire analytics, providing businesses the ability ...
(Date:7/13/2014)... Recently, TopDresses100.com, a popular dress company in the ... multi-colored Quinceanera dresses to its product line. According ... outfits are guaranteed to be quality made. Now, they ... , TopDresses100.com has a wide variety of elegant dresses ... are in stock and ready to ship. As an ...
Breaking Medicine News(10 mins):Health News:Home Health Care Professional and Marketing Firm Team Up to Create New Homecare Communication App 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 3Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 2Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 3Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2
... of different alcoholic beverages and drinking behaviour on the risk ... and Cohort of Swedish Men, to study the association between ... acute pancreatitis. In total, 84,601 individuals, aged 46-84 years, ... 513 developed acute pancreatitis. There was a doseresponse association ...
... Aug. 11 (HealthDay News) -- The HIV infection rate among ... of AIDS is 10 to 20 times greater than in ... Two percent of poor heterosexuals in those cities have ... Prevention researchers, analysis of National HIV Behavioral Surveillance System data. ...
... (WASHINGTON, August 11, 2011) According to a study ... of the American Society of Hematology (ASH), researchers ... drug that releases stem cells from the bone marrow into ... at risk for later development of abnormalities involving loss or ...
... THURSDAY, Aug. 11 (HealthDay News) -- Symptoms of Alzheimer,s ... 80, according to a new study that examined the ... The study included 105 Alzheimer,s patients and 125 ... 60 to 75 (young-old) and those 80 and older ...
... Mann HealthDay Reporter , WEDNESDAY, Aug. 10 (HealthDay ... people with an irregular heartbeat may give the old standby, ... an erratic heartbeat known as atrial fibrillation are at increased ... such as a blood clot. For this reason, they have ...
... release is available in French . , ROCKVILLE, ... Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a ... (TB) vaccine that involves people living with the human immunodeficiency ... sites in Senegal and South Africa with primary funding support ...
Cached Medicine News:Health News:Alcohol consumption in relation to acute pancreatitis 2Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Alzheimer's Harder to Detect in the Very Old 2Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 2Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 3Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 4Health News:New TB vaccine enters proof-of-concept trial in people living with HIV 2Health News:New TB vaccine enters proof-of-concept trial in people living with HIV 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: